within Pharmacolibrary.Drugs.ATC.P;

model P01BA01
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.89,
    Cl             = 2.3333333333333336e-06,
    adminDuration  = 600,
    adminMass      = 600 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.165,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.011083333333333334,
    Tlag           = 600,            
    Vdp             = 0.285,
    k12             = 1.34,
    k21             = 1.34
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>P01BA01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Chloroquine is an antimalarial and anti-inflammatory agent formerly used broadly for the prevention and treatment of malaria and certain auto-immune diseases like rheumatoid arthritis and lupus erythematosus. Its use has declined due to widespread resistance and availability of more effective drugs, but it remains on the WHO list of essential medicines. Chloroquine was also explored for use against viral infections such as COVID-19, but is not currently approved for this indication.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters from healthy adult volunteers following single oral dose.</p><h4>References</h4><ol><li><p>Liu, X, &amp; Jusko, WJ (2021). Physiologically Based Pharmacokinetics of Lysosomotropic Chloroquine in Rat and Human. <i>The Journal of pharmacology and experimental therapeutics</i> 376(2) 261–272. DOI:<a href=\"https://doi.org/10.1124/jpet.120.000385\">10.1124/jpet.120.000385</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33277347/\">https://pubmed.ncbi.nlm.nih.gov/33277347</a></p></li><li><p>Liu, LJ, et al., &amp; Zhang, H (2019). Effects of Hydroxychloroquine on Proteinuria in IgA Nephropathy: A Randomized Controlled Trial. <i>American journal of kidney diseases : the official journal of the National Kidney Foundation</i> 74(1) 15–22. DOI:<a href=\"https://doi.org/10.1053/j.ajkd.2019.01.026\">10.1053/j.ajkd.2019.01.026</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30922594/\">https://pubmed.ncbi.nlm.nih.gov/30922594</a></p></li><li><p>Yao, X, et al., &amp; Liu, D (2021). Population-based meta-analysis of chloroquine: informing chloroquine pharmacokinetics in COVID-19 patients. <i>European journal of clinical pharmacology</i> 77(4) 583–593. DOI:<a href=\"https://doi.org/10.1007/s00228-020-03032-6\">10.1007/s00228-020-03032-6</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33188451/\">https://pubmed.ncbi.nlm.nih.gov/33188451</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end P01BA01;
